1492 Telomere-targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation – A phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Chemistry

Cancer Oncology

Medicine

Pulmonary And Respiratory Medicine

Thio-

Show all topics

DOI

10.1136/jitc-2024-sitc2024.1492

License

CC-BY-NC

Other Formats

PDF